Clinical Updates in Adult Immune Thrombocytopenia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2017 Apr 19

PMID 28416506

Citations 154

Authors

Michele P Lambert

Terry B Gernsheimer

Affiliations

Soon will be listed here.

Abstract

Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable bleeding symptoms and thrombocytopenia. In the last decade, changes in our understanding of the pathophysiology of the disorder have led to the publication of new guidelines for the diagnosis and management of ITP and standards for terminology. Current evidence supports alternatives to splenectomy for second-line management of patients with persistently low platelet counts and bleeding. Long-term follow-up data suggest both efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of late remissions. Follow-up of patients who have undergone splenectomy for ITP reveals significant potential risks that should be discussed with patients and may influence clinician and patient choice of second-line therapy. Novel therapeutics are in development to address ongoing treatment gaps.

Citing Articles

Plasma Exosomes Derived from Patients with Primary Immune Thrombocytopenia Attenuate TBX21 Regulatory T Cell-Mediated Immune Suppression via MiR-363-3p.

Huang Y, Liu P, Xu Y, Qian C, Wu T, Li T Inflammation. 2025; .

PMID: 40032779 DOI: 10.1007/s10753-025-02275-8.

Impact of platelet transfusion and bleeding risk stratification in patients with immune thrombocytopenia before procedures.

Kang K, Choi Y, Lim H, Kwak K, Choi Y, Park Y Sci Rep. 2025; 15(1):5174.

PMID: 39939729 PMC: 11822007. DOI: 10.1038/s41598-025-89419-w.

Dengue Fever in an Adult Presenting as Immune Thrombocytopenic Purpura (ITP): A Case Report.

Sahoo D, Dey A, Bandyopadhyay T, Devi S, Dalei S Cureus. 2025; 16(12):e75124.

PMID: 39759744 PMC: 11700028. DOI: 10.7759/cureus.75124.

Exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells regulate Th1/Th2 balance and alleviates immune thrombocytopenia in pregnancy.

Rong Y, Lu W, Huang X, Ji D, Tang D, Huang R Hum Cell. 2024; 38(1):31.

PMID: 39699695 DOI: 10.1007/s13577-024-01162-y.

Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.

Zheng S, Perdomo J Curr Issues Mol Biol. 2024; 46(11):11942-11956.

PMID: 39590303 PMC: 11592706. DOI: 10.3390/cimb46110709.

References

Baeten D, Kuchroo V . How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013; 19(7):824-5. DOI: 10.1038/nm.3268. View

Li H, Zhang L, Zhao H, Ji L, Yang R . Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases. Chin Med J (Engl). 2005; 118(1):34-7. View

Altomare I, Cetin K, Wetten S, Wasser J . Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US. Clin Epidemiol. 2016; 8:231-9. PMC: 4920235. DOI: 10.2147/CLEP.S105888. View

Kuhne T, Imbach P, Bolton-Maggs P, Berchtold W, Blanchette V, Buchanan G . Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2002; 358(9299):2122-5. DOI: 10.1016/S0140-6736(01)07219-1. View

Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R . A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017; 130(9):1097-1103. DOI: 10.1182/blood-2017-01-761262. View

Chugh S, Darvish-Kazem S, Lim W, Crowther M, Ghanima W, Wang G . Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015; 2(2):e75-81. DOI: 10.1016/S2352-3026(15)00003-4. View

Neunert C, Noroozi N, Norman G, Buchanan G, Goy J, Nazi I . Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2014; 13(3):457-64. PMC: 4991942. DOI: 10.1111/jth.12813. View

Doobaree I, Nandigam R, Bennett D, Newland A, Provan D . Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016; 97(4):321-30. DOI: 10.1111/ejh.12777. View

Kuwana M, Kaburaki J, Ikeda Y . Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998; 102(7):1393-402. PMC: 508987. DOI: 10.1172/JCI4238. View

10.

Loustau V, Debouverie O, Canoui-Poitrine F, Baili L, Khellaf M, Touboul C . Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women. Br J Haematol. 2014; 166(6):929-35. DOI: 10.1111/bjh.12976. View

11.

Ahmed R, Devasia A, Viswabandya A, Lakshmi K, Abraham A, Karl S . Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP. Ann Hematol. 2016; 95(9):1429-34. DOI: 10.1007/s00277-016-2738-3. View

12.

Chang M, Nakagawa P, Williams S, Schwartz M, Imfeld K, Buzby J . Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003; 102(3):887-95. DOI: 10.1182/blood-2002-05-1475. View

13.

Leytin V, Mykhaylov S, Starkey A, Allen D, Lau H, Ni H . Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol. 2006; 133(1):78-82. DOI: 10.1111/j.1365-2141.2006.05981.x. View

14.

Wei Y, Ji X, Wang Y, Wang J, Yang E, Wang Z . High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2015; 127(3):296-302. DOI: 10.1182/blood-2015-07-659656. View

15.

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

16.

Nugent D, McMillan R, Nichol J, Slichter S . Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009; 146(6):585-96. DOI: 10.1111/j.1365-2141.2009.07717.x. View

17.

Hoffmeister K, Falet H . Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance. Thromb Res. 2016; 141 Suppl 2:S68-72. PMC: 5399515. DOI: 10.1016/S0049-3848(16)30370-X. View

18.

Palandri F, Polverelli N, Sollazzo D, Romano M, Catani L, Cavo M . Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016; 91(4):E267-72. DOI: 10.1002/ajh.24310. View

19.

Choi P, Roncolato F, Badoux X, Ramanathan S, Ho S, Chong B . A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015; 126(4):500-3. PMC: 4560338. DOI: 10.1182/blood-2015-03-631937. View

20.

van der Lugt N, van Kampen A, Walther F, Brand A, Lopriore E . Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang. 2013; 105(3):236-43. DOI: 10.1111/vox.12036. View